Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Evaluation of LY007 Cell Injection for Recurrent/Refractory CD20 Was Positive Tolerability, Safety, and Efficacy of B-cell Non-Hodgkin Lymphoma in Open, Single-arm Stage I Clinical Research

NCT06279611 is registered in ClinicalTrials.gov with Shanghai Longyao Biotechnology Inc., Ltd. as lead sponsor.

NCT NCT06279611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06279611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Evaluation of LY007 Cell Injection for Recurrent/Refractory CD20 Was Positive Tolerability, Safety, and Efficacy of B-cell Non-Hodgkin Lymphoma in Open, Single-arm Stage I Clinical Research
Lead sponsor
Shanghai Longyao Biotechnology Inc., Ltd.
Phase
Phase 1
Overall status
Unknown status
Start date
December 25, 2021
Completion date
May 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b-nhl